FLT-3 PROTAC

N/A

Report date: 2021/12/08 14:16:19

NME

Base Information

Drug NameFLT-3 PROTAC

Drug Alias NameFLT-3 PROTAC

ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsProteolysis

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYale University

China Registration ClassN/A

Active CompaniesYale University

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

ATC CodeN/A